GlassScriptPhysician profile
Sheeda Golian
NPI 1780034900
$1,617.84
in general payments reported to CMS, 2019-2025
23 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $191 · 2024: $416 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $281.13 | 2023-2025 | |
| Novo Nordisk INC | $255.78 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $155.10 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $121.40 | 2024-2025 | |
| Amgen INC. | $93.09 | 2023-2025 | Evenity, Otezla, Repatha |
| Inari Medical, INC. | $73.26 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $65.00 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $63.15 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $59.19 | 2023-2025 | Airsupra, Breztri |
| Medtronic, INC. | $56.31 | 2024-2025 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $55.96 | 2025 | Auvelity |
| Dexcom, INC. | $51.87 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $49.41 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.18 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $39.59 | 2024-2025 | Arexvy, Bexsero, Shingrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $29.60 | 2025 | Omnipod |
| Abbott Laboratories | $28.69 | 2025 | Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $17.02 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.16 | 2025 | Voquezna |
| Exact Sciences Corporation | $14.84 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $14.67 | 2024 | Gardasil 9, Vaxelis, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheeda Golian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.